NCT06111014 Phase 3 Terminated
Continuation Study for Latozinemab Study sponsor: Alector Inc. · ALEC
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Source history conflict The current registry record and the imported research history disagree. Conflicting historical edits are excluded from this timeline, exports and sponsor statistics while the discrepancy is investigated. The summary below follows the current registry source.
Imported research includes version dates later than the current official API record (2026-01-21). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Inspect current registry record Changes Study details Primary completion 2025-09-01 Actual
Enrollment · participants 17 Actual
Source updated 2026-01-21 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-01-21 · 5 fields changed
Participant count type Recorded edit − Previous value Estimated
Enrollment · participant count Recorded edit − Previous value count: 35; type: ESTIMATED
+ Updated value count: 17; type: ACTUAL
Completion date type Recorded edit − Previous value Estimated
Primary completion date Recorded edit − Previous value 2027-07-30
+ Updated value 2025-09-01
Recruitment status Recorded edit − Previous value Enrolling by invitation
+ Updated value Terminated
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial